CRUZIVAX publication
Development of vaccines for Chagas disease (CRUZIVAX): stakeholders' preferences and potential impacts on healthcare
Ramponi, F.; Aerts, C.; Sartor, P.; Pinazo, M.J.; Freilij, H.; Guzmán, C.A.; Malchiodi, E.; Sicuri, E.
_{Gaceta Sanitaria 37 (2023) 102275}

This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs.

D16.1: A PowerPoint presentation of the project
D16.2: A PowerPoint presentation of the Cruzivax project website
_{Click deliverable to download.}

CRUZIVAX public deliverables
D16.1: A PowerPoint presentation of the project
D16.2: A PowerPoint presentation of the Cruzivax project website
_{Click deliverable to download.}

When available, further results will be made public here and on our Zenodo Community.
https://zenodo.org/communities/cruzivax/